BioNTech SE Holds 2024 Annual General Meeting

Ticker: BNTX · Form: 6-K · Filed: May 17, 2024 · CIK: 1776985

Biontech Se 6-K Filing Summary
FieldDetail
CompanyBiontech Se (BNTX)
Form Type6-K
Filed DateMay 17, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: agm, filing, corporate-governance

TL;DR

BioNTech held its 2024 AGM on May 17th, filing a 6-K with press release and presentation.

AI Summary

On May 17, 2024, BioNTech SE held its Annual General Meeting (AGM) 2024. The company filed a Form 6-K to report on this event, including a press release and AGM presentation.

Why It Matters

The AGM is a key event where shareholders can vote on important company matters and receive updates on the company's performance and strategy.

Risk Assessment

Risk Level: low — This filing is a routine report of an annual general meeting and does not contain new financial or strategic information that would significantly alter risk.

Key Players & Entities

  • BioNTech SE (company) — Registrant
  • May 17, 2024 (date) — Date of AGM

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country or that it has filed or will file with a stock exchange.

When was BioNTech SE's 2024 Annual General Meeting held?

The 2024 Annual General Meeting (AGM) was held on May 17, 2024.

What documents were included as part of this Form 6-K filing?

This Form 6-K includes a press release and the AGM presentation from the 2024 Annual General Meeting.

What is BioNTech SE's principal executive office address?

BioNTech SE's principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany.

Does BioNTech SE file annual reports under Form 20-F or Form 40-F?

BioNTech SE indicates that it files annual reports under Form 20-F.

Filing Stats: 259 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-05-17 16:10:43

Filing Documents

From the Filing

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On May 17, 2024, BioNTech SE (the "Company") held the Annual General Meeting ("AGM") 2024. The press release and the AGM presentation are attached hereto as Exhibits 99.1 and 99.2, respectively. The voting results are attached hereto as Exhibit 99.3. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Dr. Sierk Poetting Name Sierk Poetting Title Chief Operating Officer Date May 17, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Press R elease BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024 99.2 Annual General Meeting 202 4 Presentation 99.3 Annual General Meeting 2024 Voting Results

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.